Profile: Ceregene, Inc. is a biotechnology company that focuses on the treatment of major neurodegenerative disorders using the delivery of nervous system growth factors. Our clinical programs include CERE-110, an AAV2 based vector expressing nerve growth factor, which is about to enter phase 2 studies for the treatment of Alzheimer's disease, and CERE-120, which completed a phase 2 trial in Parkinsons disease is being evaluated for future development. Our CERE-135 and CERE-140 are in preclinical development for amyotrophic lateral sclerosis and ocular diseases. We develop a pipeline of products to treat serious diseases of the brain & eyes, and all of the products use neurotrophic growth factors, coupled with gene delivery technology.